Acknowledgements Funding for the project was provided by the Dalhousie Pharmacy Endowment Fund and Studentship funding was provided by the Canadian Institutes of Health Research. Many thanks are extended to Ms Elizabeth Foy for her assistance in developing search strategies and to Dr David Gardner and Melissa MacDonald for helping with early project development. References 1. Natural health products directorate [homepage on the Internet]. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodnatur/index_ e.html (last accessed date December 13, 2007). 2. Chiappelli F, Prolo P, Rosenblum M, Edgerton M, Cajulis OS. Evidence-based research in complementary and alternative medicine II: the process of evidence-based research. Evid Based Complement Alternat Med 2006;3:3–12. 3. Sackett DL, Richardson WS, Roseberg W, Haynes RB. Evidence- based Medicine: How to Practice and Teach. New York: Churchill Livingstone, 1997. 4. Gagnier JJ, DeMelo J, Boon H, Rochon P, Bombardier C. Quality of reporting of randomized controlled trials of herbal medicine interventions. Am J Med 2006;119:e800–11. 5. Glenny AM. No ‘‘gold standard’’ critical appraisal tool for allied health research. Evid Based Dent 2005;6:100–1. 6. Katrak P, Bialocerkowski AE, Massy-Westropp N, Kumar S, Grimmer KA. A systematic review of the content of critical appraisal tools. BMC Med Res Methodol 2004;4:22. 7. Agency for healthcare research and quality: Systems to rate the strength of scientific evidence. Rockville: 2002. Report No.: Evidence Report/Technology Assessment No.47, Publication No.02-E016. 8. Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials 1995;16:62–73. 9. Busse W. The significance of quality for efficacy and safety of herbal medicinal products. Drug Inf J 2000;34:15–23. 10. Bauer R. Quality criteria and standardization of phytopharmaceu- ticals: can acceptable drug standards be achieved? Drug Inf J 1998;32:101–10. 11. Guyatt GH, Sackett DL, Cook DJ. Users’ guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? Evidence-based medicine working group. JAMA 1994;271:59–63. 12. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663–94. 13. Drug information resources: a guide for pharmacists [homepage on the Internet]. Available from: htpp://dir.pharmacy.dal.ca (last accessed date September, 2006). 14. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, et al. Reporting randomized, controlled trials of herbal interven- tions: an elaborated CONSORT statement. Ann Intern Med 2006;144:364–7. 15. Moher D, Schulz KF, Altman DG CONSORT GROUP (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001;134:657–62. 16. Bian Z, Wu T, Liu L, Miao J, Wong H, Song L, et al. Effectiveness of the chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review. J Altern Complement Med 2006;12:401–7. 17. Bian ZX, Li YP, Moher D, Dagenais S, Liu L, Wu TX, et al. Improving the quality of randomized controlled trials in chinese eCAM 2009;6(4) 447 herbal medicine, part I: clinical trial design and methodology. Zhong Xi Yi Jie He Xue Bao 2006;4:120–9. 18. Bian ZX, Moher D, Dagenais S, Li YP, Wu TX, Liu L, et al. Improving the quality of randomized controlled trials in chinese herbal medicine, part IV: applying a revised CONSORT checklist to measure reporting quality. Zhong Xi Yi Jie He Xue Bao 2006;4:233–42. 19. Chen XY, Wu TX, Liu GJ, Wang Q, Zheng J, Wei J, et al. Chinese medicinal herbs for influenza. Cochrane Database of Systematic Reviews 2005, Issue 1. Art No.: CD004559. DOI: 10.1002/14651858. CD004559. pub 2. 20. Gardner DM. Evidence-based decisions about herbal products for treating mental disorders. J Psychiatry Neurosci 2002;27:324–33. 21. Kleijnen J, Mackerras D. Vitamin E for intermittent claudication. Cochrane Database of Systematic Reviews 1998, Issue 1. Art. No.: CD000987. DOI: 10.1002/14651858. CD 000987. 22. Kleijnen J, Knipschild P, ter Riet G. Clinical trials of homeopathy. Br Med J 1991;302:316–23. 23. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St john’s wort for depression: an overview and meta-analysis of randomised clinical trials. Br Med J 1996;313:253–8. 24. Linde K, Berner M, Egger M, Mulrow C. St john’s wort for depression: Meta-analysis of randomised controlled trials. Br J Psychiatry 2005;186:99–107. 25. Low Dog T. Clinical trial reviewer’s guidance and checklist. In: Barrett M (ed). The Handbook of Clinically Tested Herbal Remedies, Vol. 1. Birmingham, New York: The Haworth Press, Inc, 2004, 141–8. 26. Qiong W, Yiping W, Jinlin Y, Tao G, Zhen G, Pengcheng Z. Chinese medicinal herbs for acute pancreatitis. Cochrane Database of Systematic Reviews 2005 , Issue 1. Art. No.: CD003631. DOI: 10.1002/14651858. CD 003631. pub 2. 27. Sarubin A. The Health Professional’s Guide to Popular Dietary Supplements. United States: The American Dietetic Association, 2000. 28. Taixiang W, Munro AJ, Guanjian L. Chinese medical herbs for chemotherapy side effects in colorectal cancer patients. Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD004540. DOI: 10.1002/14651858. CD004540. pub 2. 29. Zhang W, Leonard T, Bath-Hextall F, Chambers CA, Lee C, Humphreys R, et al. Chinese herbal medicine for atopic eczema. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD002291. DOI: 10.1002/14651858. CD002291.pub 3. 30. Hemila¨ H, Chalker E, D’Souza RRD, Douglas RM, Treacy B. Vitamin C for preventing and treating the common cold. Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No.: CD004782. DOI: 10.1002/14651858. CD004782. 31. Kjaergard LL, Villumsen J, Gluud C. Quality of randomised clinical trials affects estimates of intervention efficacy. Proceedings of the 7th cochrane colloquium. 1999. Rome: Universita S. Tommaso D’Aquino, 1999, 57. 32. Schulz KF. Subverting randomization in controlled trials. JAMA 1995;274:1456–8. 33. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. Br Med J 2001;323:42–6. 34. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology 1994;44:16–20. 35. Egger M, Juni P, Bartlett C. Value of flow diagrams in reports of randomized controlled trials. JAMA 2001;285:1996–9. 36. May GS, Chir B, Demets DL, Friedman LM, Furberg C, Passamani E. The randomized clinical trial: bias in analysis. Circulation 1981;64:669–73. 37. Sackett DL, Gent M. Controversy in counting and attributing events in clincial trials. New Engl J Med 1979;301:1410–2. 38. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998;52:377–84. 39. Sindhu F, Carpenter L, Seers K. Development of a tool to rate the quality assessment of randomized controlled trials using a delphi technique. J Adv Nurs 1997;25:1262–8.